Other News To Note
Wednesday, August 1, 2012
Antisense Pharma GmbH, of Regensburg, Germany said it has been granted orphan drug designation from the FDA for its oncology antisense compound trabedersen to treat malignant melanoma. Previously, trabedersen has received orphan drug designation by the European EMA and the FDA in high-grade glioma (malignant brain tumor) and in advanced pancreatic cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.